; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

Our R&D programs are supported by cash flow generated by Crinone® (progest  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.10 (2.50%)
Data as of 04/26/17 3:59 p.m. ET
Minimum 20 minute delayRefresh quote
JNP Corporate Overview
Recent NewsMore >>
03/29/17Juniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary EventPrinter Friendly Version
03/07/17Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating ResultsPrinter Friendly Version
03/06/17Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017Printer Friendly Version
03/01/17Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017Printer Friendly Version